Bachem Holding AG Stock Swiss Exchange
Equities
BANB
CH0012530207
Biotechnology & Medical Research
Sales 2024 * | 620M 680M | Sales 2025 * | 811M 890M | Capitalization | 6.08B 6.67B |
---|---|---|---|---|---|
Net income 2024 * | 127M 139M | Net income 2025 * | 160M 175M | EV / Sales 2024 * | 9.71 x |
Net cash position 2024 * | 64.89M 71.17M | Net Debt 2025 * | 74.85M 82.09M | EV / Sales 2025 * | 7.59 x |
P/E ratio 2024 * |
50.6
x | P/E ratio 2025 * |
38.4
x | Employees | 2,006 |
Yield 2024 * |
1.06% | Yield 2025 * |
1.15% | Free-Float | 94.31% |
Latest transcript on Bachem Holding AG
Managers | Title | Age | Since |
---|---|---|---|
Thomas Meier
CEO | Chief Executive Officer | 56 | 18-12-31 |
Alain Schaffter
DFI | Director of Finance/CFO | 47 | 21-01-31 |
Ralph Schönleber
CTO | Chief Tech/Sci/R&D Officer | - | 02-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Grogg
BRD | Director/Board Member | 82 | - |
Kuno Sommer
CHM | Chairman | 68 | 12-04-24 |
Director/Board Member | 51 | 11-04-12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 18 M€ | +3.90% | - |
1st Jan change | Capi. | |
---|---|---|
+3.13% | 42.11B | |
+48.83% | 40.08B | |
+8.49% | 40B | |
-10.82% | 26.87B | |
+8.26% | 24.58B | |
-23.69% | 18.44B | |
+1.58% | 11.94B | |
+32.83% | 11.66B | |
+6.63% | 11.01B |